Efficacy and safety of intravenous leukotriene receptor antagonists in acute asthma

Qahtani, Shaya Yaanallah Al

doi:10.1016/j.amjms.2023.04.012

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Leukotrienes, as an inflammatory mediator, participate in the occurrence and development of BPD in preterm infants [39,40]. Montelukast, as an effective cysteinyl leukotriene receptor antagonist, has a high affinity for leukotriene receptors, thus blocking leukotriene action, effectively controlling the aggregation of inflammatory cytokines and reducing the secretion of inflammation [41,42]. In addition, montelukast also plays an anti-inflammatory and immunomodulatory role by inhibiting the activities of 5-lipoxygenase and nuclear factor-kappa B signaling pathways [43,44].…”

Section: Discussionmentioning

confidence: 99%

Montelukast Sodium to Prevent and Treat Bronchopulmonary Dysplasia in Very Preterm Infants: A Quasi-Randomized Controlled Trial

Sun,

Lu,

Yang

et al. 2023

JCM

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease in preterm infants and lacks effective methods for prevention and treatment. The aim of this study is to explore the efficacy and safety of montelukast in preventing or treating BPD in preterm infants. The preterm infants with BPD risk factors were divided randomly into a montelukast group and a control group. In the montelukast group, preterm infants were given 1 mg/kg of montelukast sodium daily. There was no placebo in the control group. There was no significant difference in the incidence of moderate or severe BPD between the two groups (31.8% vs. 35%). The duration of respiratory support in the montelukast group was shorter than that in the control group (36.4 ± 12.8 d vs. 43.1 ± 15.9 d, p = 0.037). The pulmonary severity score (PSS) at 21 days of life in the montelukast group was significantly lower than that in the control group (0.56 ± 0.13 vs. 0.62 ± 0.14, p = 0.048). There were no significant differences in the duration of mechanical ventilation, length of stay, hospitalization expenses, or incidence of adverse events. Although montelukast cannot alleviate the severity of BPD, it may shorten the duration of respiratory support and decrease the PSS in very preterm infants. There were no significant adverse drug events associated with montelukast treatment.

show abstract